Opendata, web and dolomites

ViaOne

A MINIMALLY INVASIVE NEEDLE FREE DEVICE TO SAFELY ACCESS THE PERICARDIUM SPACE

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 ViaOne project word cloud

Explore the words cloud of the ViaOne project. It provides you a very rough idea of what is the project "ViaOne" about.

600m    expertise    confident    failed    5m    cardiac    representing    tamponade    free    price    sme    variety    epicardial    ensures    30    needle    penetration    invasive    workspace    cardiovascular    procedure    11m    clinical       arrhythmia    first    employs    puncture    acute    financial    disorders    business    device    techniques    bleeding    pathologies    reduce    performed    safe    pathological    space    avoiding    successful    commercial    needles    competitive    pct    outcomes    big    atrial    ablations    catheters    130    050670    treatment    il2018    fact    250    epiviasystem    surgery    structured    skill    motion    af    electrohpysiological    pericardium    geometrically    24m    2016    medical    healthcare    patients    feasibility    deaths    constant    heart    area    people    ablation    fibrillation    marketable    release    commercialize    complications    market    equivalent    mapping    requiring    2021    optimize    patient    manner    pericardial    secure    thread    additional    tools    opportunity   

Project "ViaOne" data sheet

The following table provides information about the project.

Coordinator
CARDIOVIA LTD. 

Organization address
address: WADI EL HAJ 13
city: NAZARETH
postcode: 1600101
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Project website https://www.cardiovia.com/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-05-01   to  2019-09-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CARDIOVIA LTD. IL (NAZARETH) coordinator 50˙000.00

Map

 Project objective

2.5M patients per year in the US and the EU require pericardial space access as the result of a variety of pathological conditions. Atrial Fibrillation (AF) is the most common condition requiring pericardial access, in fact, AF affected 24M people in the US and 11M in the EU (2016). In current epicardial access techniques (using needles), complications can reach 4.5-30% (representing a Ëž€600M/year increase in costs for healthcare systems) and includes heart puncture, cardiac tamponade and pericardial bleeding, which can result in an increase in patient deaths. The use of a needle in the heart area, which is in constant motion, requires a high level of skill and expertise during surgery. EpiVIASYSTEM is the first device (PCT /IL2018 /050670) to ensure pericardial access in a confident, safe, needle-free manner avoiding complications during penetration of the pericardium. The device employs a unique geometrically structured thread that ensures a secure workspace for the use of additional cardiovascular devices, such as mapping and ablation catheters for treatment of arrhythmia disorders. Its design will ensure a competitive price of €250/procedure when compared with €130 for the equivalent tools used in invasive non-electrohpysiological procedures. EpiVIASYSTEM is expected to improve clinical outcomes of patients and reduce costs associated with failed ablations associated with the needle use by €600M/year. The increased growth of cardiac pathologies and the 2.5M of patients/year that require pericardial access represent a big business opportunity for the EpiVIASYSTEM and will favour its successful market uptake. EpiVIASYSTEM´s main objective is to optimize, scale-up and commercialize a marketable medical device in both the EU and the US by 2021. For that, a feasibility study will be performed during SME Phase 1 to evaluate any technical, commercial and/or financial issues and ensure the successful release of the EpiVIASYSTEM into the market.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "VIAONE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "VIAONE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Colourganisms (2020)

Microbial production of custom-made, pure and sustainable anthocyanins

Read More  

RoboSynFarm (2019)

Robotic Synthesis Farm

Read More  

BeatsDigTherapeutics (2019)

Project SCALE: Tailored Digital Therapeutics for Neurological and Brain Disorders

Read More